KJHP
JSPRW icon

K.J. Harrison & Partners’s Japer Therapeutics Warrants JSPRW Stock Holding History

K.J. Harrison & Partners’s Portfolio JSPRW Stock Details JSPRW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-10,000
Closed -$12 – 396
2021
Q2 		$12 Hold
10,000
– – ﹤0.01% 341
2021
Q1 		$8K Buy
+10,000
New +$14.6K ﹤0.01% 330

Other funds holding JSPRW

OCAM
Owl Creek Asset Management New York $1.38B AUM 59.67% 1-Year Est. Return
HCM
Highbridge Capital Management New York $3.09B AUM 31.19% 1-Year Est. Return
TCM
Tenor Capital Management New York $6.49B AUM 3.01% 1-Year Est. Return
SCM
Shaolin Capital Management Miami, Florida $2.71B AUM 64.83% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return
ZA
Zazove Associates Incline Village, Nevada $1.22B AUM 1.91% 1-Year Est. Return
MS
Maven Securities St Helier, Jersey $5.2B AUM 44.01% 1-Year Est. Return
RCM
Rivernorth Capital Management West Palm Beach, Florida $2B AUM 0.66% 1-Year Est. Return
BI
Bulldog Investors Saddle Brook, New Jersey $445M AUM 2.55% 1-Year Est. Return
Walleye Trading
Walleye Trading New York $60B AUM 42.19% 1-Year Est. Return

K.J. Harrison & Partners's JSPRW Position: Q3 2021 in Review

K.J. Harrison & Partners sold out of Japer Therapeutics Warrants (JSPRW) in Q3 2021, closing a stake of 10,000 shares — an estimated $12 sold.

K.J. Harrison & Partners first reported a position in JSPRW in Q1 2021 and held it in 2 quarters. The position peaked at $8K in Q1 2021. 16 funds tracked by Wall St. Rank hold JSPRW as of Q3 2021.

  • K.J. Harrison & Partners reported no remaining Japer Therapeutics Warrants position as of Q3 2021 after selling out during the quarter.
  • K.J. Harrison & Partners sold 10,000 Japer Therapeutics Warrants shares in Q3 2021, an estimated $12.
  • K.J. Harrison & Partners first reported a position in Japer Therapeutics Warrants in Q1 2021 and held it in 2 quarters.
  • K.J. Harrison & Partners's Japer Therapeutics Warrants position peaked at $8K in Q1 2021.
  • 16 funds tracked by Wall St. Rank held Japer Therapeutics Warrants as of Q3 2021.

Based on K.J. Harrison & Partners's 13F filing for Q3 2021, filed 5 Nov 2021.